title: BMP-2 and bFGF in an irradiated bone model.
abstract: BACKGROUND
  Basic fibroblast growth factor (bFGF) is considered to enhance angiogenesis and to support bone formation in the presence of vital bone cells. Bone morphogenetic protein-2 (rhBMP-2) is known to induce bone formation. The aim of this study was to analyze the effect of bFGF and rhBMP-2 in the irradiated mandible.
  
  
  METHODS
  The right mandibles of 24 rats were irradiated with a single dose of 20 Gy at a high-dose-rate (HDR) after loading machine (bio effective equivalent dose to ca. 45 x 2 Gy). After 12 weeks 100 microg rhBMP-2 (n=6 animals, group 1), 100 microg bFGF (n=6 animals, group 2) and 100 microg rhBMP-2 plus 100 microg bFGF (n=6 animals, group 3) were injected along the right mandible (left mandible: no irradiation, no growth factor). Another 6 animals (group 4) remained untreated after the irradiation. After another 7 weeks the specimens were examined by non-decalcified histology.
  
  
  RESULTS
  Bone apposition of the experimental versus control sides was not statistically significantly different when one of the growth factors was applied alone (rhBMP-2: p=0.917; bFGF: p=0.345). Average bone apposition was significantly decreased on the experimental sides of group 3 (rhBMP-2+bFGF: p=0.046) and group 4 (p=0.008). Average bone densities were unaffected in all settings (for all p>0.1).
  
  
  CONCLUSIONS
  The application of bFGF and the application of rhBMP-2 alone did result in predictable bone generation in the irradiated mandible with the bone apposition being equal to that of the non-irradiated side. The application of both growth factors together or none at all after irradiation results in significantly reduced bone apposition.
authors.affiliation: Department of Oral and Maxillofacial Surgery, University of Kiel, Germany. springer@mkg.uni-kiel.de
authors.forename: Ingo N G
authors.initials: IN
authors.lastname: Springer
authors.forename: Peter
authors.initials: P
authors.lastname: Niehoff
authors.forename: Yahya
authors.initials: Y
authors.lastname: Açil
authors.forename: Matthias
authors.initials: M
authors.lastname: Marget
authors.forename: Arne
authors.initials: A
authors.lastname: Lange
authors.forename: Patrick H
authors.initials: PH
authors.lastname: Warnke
authors.forename: Helge
authors.initials: H
authors.lastname: Pielenz
authors.forename: J Camilo
authors.initials: JC
authors.lastname: Roldán
authors.forename: Jörg
authors.initials: J
authors.lastname: Wiltfang
mesh_terms: D000818:Animals; D015519:Bone Density / Q000187:drug effects / Q000528:radiation effects; D055396:Bone Morphogenetic Protein 2; D019485:Bone Morphogenetic Proteins / Q000494:pharmacology*; D001861:Bone Regeneration / Q000187:drug effects / Q000528:radiation effects; D016222:Fibroblast Growth Factor 2 / Q000494:pharmacology*; D006801:Humans; D008334:Mandible / Q000187:drug effects* / Q000528:radiation effects*; D023421:Models, Animal; D010025:Osteoradionecrosis / Q000503:physiopathology; D011882:Radiotherapy, High-Energy / Q000009:adverse effects*; D051381:Rats; D011916:Rats, Inbred F344; D011917:Rats, Inbred Lew; D011921:Rats, Inbred WKY; D011994:Recombinant Proteins / Q000494:pharmacology; D018709:Statistics, Nonparametric; D016212:Transforming Growth Factor beta / Q000494:pharmacology*
chemical_list: C525718:BMP2 protein, human; C525720:Bmp2 protein, rat; D055396:Bone Morphogenetic Protein 2; D019485:Bone Morphogenetic Proteins; D011994:Recombinant Proteins; D016212:Transforming Growth Factor beta; D016222:Fibroblast Growth Factor 2